A two-sample Mendelian randomization (MR) study evaluated whether genetically predicted increased GLP-1 receptor (GLP1R) expression has a causal effect on male pattern hair loss (androgenetic alopecia).
The MR analysis suggested a causal relationship between increased GLP1R expression and male pattern hair loss, implying that GLP-1R signaling may promote androgenetic alopecia in men.
Mendelian randomization relies on genetic instruments as proxies for GLP1R expression and cannot confirm biological mechanisms; findings may not generalize across ancestries if GWAS data were ancestry-specific; reverse causation and horizontal pleiotropy remain potential confounders despite MR design.
Clinicians prescribing GLP-1 receptor agonists (e.g., semaglutide, liraglutide) should be aware of a possible causal link between GLP1R activity and male pattern hair loss, and may consider monitoring male patients for alopecia. This finding warrants prospective clinical validation before changing prescribing practice.
